FOR IMMEDIATE RELEASE

Contact:  Tom Herrick
          Investor Relations
          (805) 685-9880

                       ROBERT SUTCLIFFE AND MICHAEL KHOURY
                        JOIN MIRAVANT BOARD OF DIRECTORS

SANTA BARBARA,  Calif., January 31, 2005 - Miravant Medical Technologies (OTCBB:
MRVT),  a  pharmaceutical  development  company  specializing  in  PhotoPoint(R)
photodynamic therapy (PDT), announced today the elections of Robert J. Sutcliffe
and Michael Khoury to its board of directors.

Robert Sutcliffe, a venture lawyer and business advisor based in Los Angeles, is
the managing  director of Craftsman Capital Advisors LLC, and specializes in the
representation  of entrepreneurs  and venture investors in a range of industries
including  biotechnology.  A graduate of UCLA and  Harvard  Law  School,  he was
partner  and group  chairman in a  corporate  law firm until  1989,  focusing on
venture   capital,   corporations   and  securities.   He  then  served  as  the
congressional  chief of staff to the Honorable  Christopher  Cox of  California.
Subsequently he was director,  chief  operating  officer and general counsel for
International  Medication Systems Limited, a manufacturer of pharmaceuticals and
drug delivery devices. In 1995 he co-founded Digital Gene Technologies,  Inc., a
genomics-based  drug  discovery  and  development  company,  where he  served as
director,  president and chief executive  officer.  He is a founding director of
Neurome,   Inc.,  a  discovery-stage   biotechnology   company  specializing  in
therapeutics for neurodegenerative diseases.

Michael  Khoury,  a  Los  Angeles-based  independent  consultant  to  a  private
investment group, holds an MFA from New York University  (Fulbright Scholar) and
an MBA from the UCLA Anderson Graduate School of Management.  A certified public
accountant,  he was a senior  manger with  Deloitte & Touch until 1993.  He then
served as  president  and chief  executive  officer of First  National  Mortgage
Exchange,  Inc.,  which he  rebuilt  and sold in 1998 to  FirstPlus,  a  leading
NYSE-traded  mortgage bank. He  subsequently  served as senior vice president of
IMC Mortgage,  a consumer  finance  company.  In 1999 he became chief  executive
officer of InterScore, a consulting firm specializing in E-commerce engineering,
successfully selling the firm in 2000 to Ballantyne, an information technologies
consulting and staffing  company.  He currently serves as director on the boards
of Neurome, Inc. and SourcingLink, Inc.

Gary S.  Kledzik,  PhD,  chairman and chief  executive  officer,  stated,  "I am
extremely  pleased  with the  additions  of Bob  Sutcliffe  and Mike  Khoury  to
Miravant's board of directors,  both experienced  entrepreneurs  with impressive
business and financial strengths."

About Miravant

Miravant Medical  Technologies  specializes in  pharmaceuticals  and devices for
photoselective medicine,  developing its proprietary PhotoPoint(R)  photodynamic
therapy  (PDT)  for  large  potential  markets  in  ophthalmology,  dermatology,
cardiovascular   disease  and  oncology.   PhotoPoint  PDT  uses   photoreactive
(light-activated)  drugs to selectively target diseased cells and blood vessels.
The Company's lead drug, Photrex(TM),  is in clinical development as a treatment
for wet age-related  macular  degeneration and has received an approvable letter
from the U.S. Food and Drug Administration.  Miravant's  cardiovascular  program
focuses on life-threatening  coronary artery diseases, with PhotoPoint MV0633 in
advanced  preclinical testing for  atherosclerosis,  atherosclerotic  vulnerable
plaque and restenosis.

                                                      # # #